MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2 positive (HER2 +) breast cancer (BC). Some patients show resistance to trastuzumab, and scientists want to circumvent this problem. This review elabora...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseinzadeh, Aysooda, Merikhian, Parnaz, Naseri, Nazanin, Eisavand, Mohammad Reza, Farahmand, Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897942/
https://www.ncbi.nlm.nih.gov/pubmed/35248049
http://dx.doi.org/10.1186/s12935-022-02523-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897942/
https://www.ncbi.nlm.nih.gov/pubmed/35248049
http://dx.doi.org/10.1186/s12935-022-02523-z

Ejemplares similares